Assessing the impact and cost-effectiveness of long-acting PrEP for HIV prevention

Epidemiological Impact and Cost-effectiveness of Long-acting Antiretrovirals for Pre-exposure Prophylaxis Among Key Populations in Thailand

NA · Institute of HIV Research and Innovation Foundation, Thailand · NCT05774548

This study is testing how well long-acting PrEP works for preventing HIV and whether it's worth the cost by talking to HIV-negative men who have sex with men and transgender women about their preferences.

Quick facts

PhaseNA
Study typeInterventional
Enrollment10720 (estimated)
Ages18 Years and up
SexMale
SponsorInstitute of HIV Research and Innovation Foundation, Thailand (other)
Locations12 sites (Bangkok, Bangkapi and 11 other locations)
Trial IDNCT05774548 on ClinicalTrials.gov

What this trial studies

This study evaluates the impact and cost-effectiveness of long-acting PrEP through discrete choice experiments and analysis of routine service data. It involves conducting in-depth interviews and focus group discussions with HIV-negative men who have sex with men (MSM) and transgender women (TGW) to identify key attributes influencing PrEP use. The findings will inform mathematical modeling to assess user preferences and the overall effectiveness of PrEP strategies. The study aims to provide insights that can enhance PrEP uptake and optimize resource allocation in HIV prevention.

Who should consider this trial

Good fit: Ideal candidates for this study are HIV-negative MSM and TGW aged 18 and older who have shown interest in, currently use, or have previously used PrEP.

Not a fit: Patients who are not willing to participate in the study or do not meet the eligibility criteria will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved strategies for increasing PrEP uptake among at-risk populations, ultimately reducing HIV transmission rates.

How similar studies have performed: Other studies have successfully utilized discrete choice experiments to inform healthcare decision-making, indicating that this approach is both valid and potentially impactful.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Minimum age of 18 years
* Individual assigned male at birth reporting sex with men in the past 12 months
* Self-reported HIV-negative MSM and TGW who either report interest in PrEP use, current PrEP use, or past PrEP use
* Permit audio recording during the interview and/or discussion.

Exclusion Criteria:

* Not willing to participate in the study

Where this trial is running

Bangkok, Bangkapi and 11 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Hiv, HIV, PrEP

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.